A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design

BACKGROUND: Chronic kidney disease (CKD) is public health concern even in Asian countries. TRK-100STP, a sustained release tablet of an orally-active prostacyclin analogue, beraprost sodium, is suggested to suppress worsening of some parameters of renal filtration function, containing in slope of 1/...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamoto, Hidetomo, Fujita, Toshiro, Origasa, Hideki, Isono, Masanao, Kurumatani, Hajimu, Okada, Kiyonobu, Kanoh, Hiroyuki, Kiriyama, Takashi, Yamada, Shunsuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181382/
https://www.ncbi.nlm.nih.gov/pubmed/25233856
http://dx.doi.org/10.1186/1471-2369-15-153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181382/
https://www.ncbi.nlm.nih.gov/pubmed/25233856
http://dx.doi.org/10.1186/1471-2369-15-153

Ejemplares similares